Tempest Therapeutics enters a Phase 3 trial for its liver cancer drug amezalpat, in collaboration with Roche. The trial follows positive data from a Phase 2 study showing improved survival in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback